Faculty introduction, disclosures

Introduction content: cursory refresher and review Epidemiology: statistics by severity Causes and risk factors Clinical features, presentation, histopathology, BRCA status Pathogenesis, DNA damage response Diagnosis and present controversies in screening practices Staging, comorbidities, and complications

Treatment strategies in ovarian cancer How has the treatment landscape changed in the last decade, and where is it going? Mechanisms of action and impact on biochemical pathways and the cell life cycle Recurrent disease: platinum-sensitive vs. not Emerging therapies and their mechanisms, including targeted: VEGF, PARP, BRCA mutated, PD-1, wee1 kinase, TSP-1, HIF-1a, HDAC-4, tumor treating fields Safety profiles of current and emerging agents Updates in the recent clinical literature Clinical pearls in current practice: the ongoing relationship between healthcare professional and patient – education and other barriers to care Best practice: putting it all together Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Identify patients who may benefit from screening of ovarian cancer and discuss current clinical controversies around screen practices.
• Describe present treatment strategies for ovarian cancer, weighing their risk-benefit profiles in the setting of patient cases, and identify emerging treatment, discussing their potential or anticipated place(s) in therapy.
• Recognize the appropriate therapeutic choices in individual patients with ovarian cancer based on their demographic and clinical characteristics, applying them to patient cases.
• Describe the importance of the role of the healthcare professional as educator in the treatment of patients with ovarian, and brainstorm other ways in which the provider might help the patient overcome other barriers in care.

ACCME Activity #0

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: June Y. Hou, MD, Assistant Professor of Gynocologic Oncology, Columbia University, Ervings Medical Center, New York, has received financial compensation as a consultant for Foundation Medicine, Inc., Massive Bio, Inc., and Immunogen Inc.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by an educational grant from Merck.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version